Obesity treatment

On this page

Obesity treatment should make life healthier and more manageable: less breathlessness, better sleep, easier movement, and a lower risk of complications. The number on the scale helps us follow progress, but it does not tell the whole story.

Effective treatment may include changes in eating and activity, medication, and, for some people, metabolic surgery. Semaglutide and tirzepatide have become central options because they can substantially reduce appetite and body weight. Choosing treatment still requires a practical discussion of safety, nutrition, cost, and how to maintain the benefit. This guide addresses adults receiving care in the United States; medication information and advertised prices were checked on October 17, 2026.

How obesity affects health

Excess body fat, particularly around internal organs, can contribute to type 2 diabetes, high blood pressure, cardiovascular disease, obstructive sleep apnea, fatty liver disease, and joint problems. Obesity is also associated with several cancers. The combination of conditions matters more than a single weight measurement. Two people with the same body mass index can have quite different health risks. NIDDK: understanding overweight and obesity.

BMI is weight adjusted for height. In adults, 25–29.9 is conventionally called overweight and 30 or higher obesity. It is a screening measure, not a complete diagnosis: it does not directly measure body fat, muscle, fitness, or the effect of weight on your health. Waist size, blood pressure, laboratory results, symptoms, and physical function help put it in context.

Mood, self-esteem, and everyday life

Weight can affect sleep, sex, mobility, confidence, and participation in activities you enjoy. Stigma and repeated advice to “just try harder” can add a separate burden. Depression, anxiety, and binge eating deserve attention in their own right; a weight prescription is not a substitute for mental health care.

Useful goals might be walking farther without stopping, playing with your children, feeling more comfortable in an airplane seat, or needing less treatment for a weight-related condition. These changes can matter before a person reaches a particular BMI. No responsible clinician can convert a promised number of pounds lost into a guaranteed number of extra years of life.

Why weight is difficult to change

Weight reflects biology and circumstances as well as behavior. Genes, appetite regulation, sleep, medications, chronic stress, access to food, and opportunities for activity all contribute. Some medical conditions also affect weight. After weight loss, hunger can increase and energy needs fall, making maintenance harder than the initial loss. NIDDK: factors affecting weight.

A useful assessment asks what has changed in your life and health, what previous efforts achieved, and why they became difficult to sustain. It also reviews medications that may promote weight gain. Any change to an antidepressant, insulin, steroid, or other necessary treatment should be coordinated with its prescriber.

What an obesity evaluation should include

Start with your weight history, medical conditions, current prescriptions and supplements, sleep, eating patterns, activity, and previous treatments. Measurements usually include weight, height, waist circumference, and blood pressure. The examination and tests should answer questions that could change care.

Depending on the history and available records, this may include glucose or A1C, cholesterol, kidney function, and liver tests, with further assessment for sleep apnea or liver fibrosis when indicated. Thyroid testing can be appropriate; broad hormone panels, cortisol testing, genetic panels, and repeated body scans are not automatically necessary for everyone. Symptoms and examination findings should guide additional investigation. The ADA’s 2026 obesity standards emphasize assessment of complications and function alongside body size.

Tell the clinician about pregnancy plans, previous pancreatitis, gallstones, severe digestive symptoms, eating disorders, and any family history of medullary thyroid cancer. These details can change medication selection.

Setting goals that matter

An initial loss of 5–10% is a reasonable goal for many adults. At 220 pounds, that is 11–22 pounds. It can improve several weight-related problems; larger losses may offer additional benefits when they can be achieved safely. The goal is individualized rather than a deadline everyone must meet. NIDDK: choosing a weight-management program.

Track more than pounds: blood pressure, glucose, sleep, strength, symptoms, medication burden, and quality of life. Weight maintenance can itself be a successful phase of treatment. A plateau is a reason to review the plan, not automatically to prescribe a higher dose.

Comparing treatment options

Results depend on the treatment, its duration, the individual, and whether it remains accessible. Trial averages are useful for discussion, but they are not promises. Comparisons between separate studies are especially imperfect.

Selected treatment options and what the evidence can tell us

Approach	What to expect	Practical considerations
Nutrition, activity, and behavioral support	Can improve health and support weight loss and maintenance; outcomes vary with the intensity of support.	The plan must fit your health, food preferences, schedule, and resources.
Semaglutide 2.4 mg weekly	In STEP 1, average loss was 14.9% versus 2.4% with placebo at 68 weeks, alongside lifestyle intervention.	The study involved adults without diabetes; individual results vary. STEP 1.
Tirzepatide weekly	In SURMOUNT-1, average loss was 15.0–20.9%, depending on dose, versus 3.1% with placebo at 72 weeks.	The study involved adults without diabetes, with diet and activity support. SURMOUNT-1.
Metabolic/bariatric surgery	Can produce substantial, durable weight loss and improvement in metabolic disease.	Requires specialist assessment, an operation, and lifelong nutritional and medical follow-up.

When surgery belongs in the discussion

ASMBS/IFSO guidelines recommend surgery at BMI 35 or higher, regardless of accompanying conditions, and support consideration in selected people with BMI 30–34.9 and metabolic disease or inadequate durable benefit from nonsurgical treatment. Clinical recommendations and an insurer’s coverage criteria may differ. A bariatric team should assess benefits, surgical risks, preferences, and follow-up needs. Medication and surgery can complement one another, including when weight returns after an operation. ASMBS/IFSO guidance.

Eating, movement, and behavioral support

The best eating plan is nutritionally adequate and realistic enough to continue. A smaller energy intake need not mean a rigid diet or eliminating entire food groups. Regular meals, protein-containing foods, vegetables, fruit, legumes, whole grains, and appropriate portions can provide a useful foundation. Food preferences, diabetes, kidney disease, gastrointestinal symptoms, and budget may require adjustments.

Activity improves fitness even when weight changes little. Build gradually toward a level you can sustain, combining aerobic movement with strength work. For many adults, general guidance is at least 150 minutes of moderate activity each week and muscle-strengthening activity on two days; pain, disability, and medical conditions may require a different starting point. NIDDK: healthy eating and activity.

CBT and structured programs

Cognitive behavioral therapy can help address thoughts, emotions, and behaviors that sustain eating difficulties. Binge-eating disorder and other eating disorders may require specialized treatment. Structured behavioral programs and meal replacements are additional options: meal replacements substitute nutritionally formulated products for some or all meals within a defined plan. They are most useful with appropriate supervision and a plan for returning to ordinary food. They are discussed here as options available through suitable programs and professionals, rather than as a required package for every patient. NIDDK: treatment options.

How my clinical experience shapes treatment

My background includes work in a Kaiser obesity clinic, where meal replacements were part of a yearlong program. I have also used CBT in clinical practice. These experiences showed me the value of sustained support and the difficulty of maintaining results when hunger remains strong.

Semaglutide and tirzepatide have shifted the emphasis of my obesity care toward medication, together with nutrition, activity, and preservation of strength. Psychological treatment remains important when an eating disorder is present. I do not perform bariatric operations; surgical treatment requires a bariatric team, with medical care coordinated around it when appropriate.

Who may benefit from medication?

For many weight-management medicines, the usual adult eligibility thresholds are BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition, such as hypertension, abnormal cholesterol, or type 2 diabetes. Meeting a threshold opens a discussion; it does not establish that every medicine is suitable or that insurance will cover it. NIDDK: prescription weight-management medicines.

Medication can be considered alongside changes in eating and activity without requiring a person to repeat years of unsuccessful dieting. Selection should account for the amount of weight loss needed, accompanying disease, contraindications, tolerability, preferences, and the likelihood of continuing treatment.

Semaglutide and tirzepatide

Semaglutide activates the GLP-1 receptor. Tirzepatide acts at both GIP and GLP-1 receptors. Both influence appetite and satiety; they also affect glucose regulation and stomach emptying. Patients may notice less hunger or fewer persistent thoughts about food. Nausea is not the intended mechanism of weight loss. Zepbound prescribing information.

What a direct comparison showed

In SURMOUNT-5, 751 adults with obesity without diabetes were randomized to tirzepatide or semaglutide. At 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. The trial was open-label and funded by Lilly. It compared maximum tolerated tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg; it did not compare tirzepatide with the newer 7.2 mg semaglutide dose. The result supports greater average weight loss in that comparison, not superiority for every patient or every health outcome. SURMOUNT-5.

U.S. brands, formulations, and indications

Brand names and indications matter. Wegovy is semaglutide for weight management; Zepbound is tirzepatide for weight management. Ozempic and Rybelsus are semaglutide products approved for type 2 diabetes, while Mounjaro is the diabetes brand of tirzepatide. Their additional indications differ. Sharing an active ingredient does not make products, doses, devices, or insurance approvals interchangeable. MedlinePlus: products and uses.

Wegovy now includes a daily tablet and weekly injections. In March 2026, FDA approved Wegovy HD 7.2 mg for weight management in certain adults. It is an escalation option after tolerating 2.4 mg when additional weight reduction is clinically indicated, not a starting dose or a new universal target. FDA: Wegovy HD.

Oral treatment is already available

Wegovy tablets contain semaglutide, with a maintenance dose of 25 mg daily after gradual escalation. They must be taken on an empty stomach in the morning with no more than 4 ounces of water, followed by a wait of at least 30 minutes before food, other drinks, or oral medicines. The oral and injected milligram doses cannot be compared directly. Wegovy prescribing information.

Foundayo is the brand name of orforglipron, an oral GLP-1 receptor agonist approved by FDA on April 1, 2026, for weight management in eligible adults. It can be taken with or without food. Tablets may be more convenient for some people, but they still require dose escalation and safety monitoring; they are not automatically safer or more effective than injections. FDA: Foundayo approval.

Other established oral options remain useful for selected patients:

Medicine	Main considerations
Phentermine/topiramate ER (Qsymia)	A long-term treatment option. Pregnancy must be avoided because of fetal risk; pregnancy testing and effective contraception are important. Glaucoma, hyperthyroidism, and certain drug interactions can rule it out. FDA information.
Naltrexone/bupropion ER (Contrave)	Unsuitable with uncontrolled hypertension, seizure disorders, or ongoing opioid treatment, among other contraindications. It can interfere with opioid pain treatment and requires review of psychiatric history and other medicines. Prescribing information.
Orlistat (Xenical; lower-dose Alli)	Reduces fat absorption. Oily stools and urgency can limit use; interactions and fat-soluble vitamin intake need attention. Average weight loss is generally smaller than with newer incretin medicines. MedlinePlus: orlistat.

Liraglutide (Saxenda) is another injectable option, taken daily. Phentermine alone has an FDA indication for short-term use; it should not be confused with the long-term indication for the phentermine/topiramate combination. The full medication list and health history determine which alternatives are reasonable.

Access, insurance, and actual medication costs

Access is part of treatment planning. A drug that is affordable for one month but impossible to continue may be a poor fit. List price, a pharmacy’s cash quote, a manufacturer self-pay offer, and your insurance copayment are different prices.

Ask your prescription plan whether the exact product is covered for your diagnosis, whether prior authorization is required, what documentation it needs, and what renewal criteria apply. Also check the deductible, pharmacy network, and expected cost after any savings expire. Approval for a diabetes drug does not automatically cover treatment of obesity in a person without diabetes.

There have been real price reductions: Novo Nordisk reduced its standard self-pay price for Wegovy injections from $499 to $349 a month in November 2025. This was a change to a particular purchasing program, not a universal reduction in every patient’s copayment. Manufacturer announcement.

Treatment can still cost several hundred dollars a month. These are examples of advertised U.S. offers checked on October 17, 2026, not a quote or guarantee:

Advertised manufacturer self-pay options

Product	Advertised medication price and key conditions
Wegovy tablets	$149/month at 1.5 mg; $199 at 4 mg; $299 at 9 or 25 mg. A month is 30 tablets. Novo Nordisk terms.
Wegovy pens	For eligible new participants, $199 per month for two introductory fills at 0.25/0.5 mg through December 31, 2026; then $349 for standard doses. HD 7.2 mg is $399. A month is four pens. Novo Nordisk terms.
Zepbound self-pay program	$299 at 2.5 mg, $399 at 5 mg, and a $449 offer at 7.5–15 mg for specified presentations. The higher-dose offer requires timely refills within 45 days. Check the exact vial or KwikPen program. Lilly terms.
Foundayo through LillyDirect	From $149 at 0.8/2.5 mg, $199 at 5.5 mg, and $299 at 9–17.2 mg. Reduced 2.5/5.5 mg prices run through December 31, 2026; the 14.5/17.2 mg offer requires refills within 45 days. LillyDirect terms.

Eligibility restrictions, presentations, refill timing, and expiration dates matter. Programs can change; consultation, laboratory work, and other charges are separate unless explicitly included. Commercial insurance savings cards have their own eligibility rules and generally exclude government insurance. An advertised “as little as $25” is not the price every insured patient pays.

Medicare has also changed: the Medicare GLP-1 Bridge began July 1, 2026, offering selected medicines for a $50 monthly copayment to eligible beneficiaries. It does not mean every Medicare patient qualifies. Check the current criteria and authorization process with the program rather than assuming universal coverage. CMS: Medicare GLP-1 Bridge. If you have Medicare, discuss access with a clinician who can provide your care under the applicable rules. Oparin Medical currently cannot accept Medicare patients, including for self-pay visits.

Compounded medicines: access, limits, and risks

Patients often turn to compounding because branded drugs are expensive, insurance declines coverage, or a particular product is difficult to obtain. Those problems are real. A lower price, however, does not establish that a compounded product is equivalent to an approved medicine.

Compounded drugs are not FDA-approved products and do not undergo the same premarket review of safety, effectiveness, and quality. Compounding can serve legitimate individual medical needs. It is different from an FDA-approved generic, and a compounded medicine should not be advertised as though it were an approved generic Wegovy or Zepbound. FDA: understanding compounded-drug risks.

The rules changed after FDA resolved the national shortages. Under section 503A, patient-specific compounding remains subject to restrictions on routinely making essentially copies of commercially available drugs. A prescriber may document a change that makes a significant difference for an identified patient; cost alone does not create that medical distinction. FDA: section 503A guidance.

Under section 503B, outsourcing facilities face additional restrictions on using bulk ingredients. FDA states that semaglutide and tirzepatide are currently neither on its shortage list nor on the 503B bulks list. Adding B12 does not automatically turn a copy into a clinically necessary individualized product. FDA: current compounding policy.

Safety problems include incorrect concentrations, dosing errors, inadequate storage, and fraudulent labeling. “Units” on a syringe are a volume measurement, not a universal semaglutide or tirzepatide dose: a different vial may contain a different amount of drug in the same volume. FDA: dosing-error alert.

Semaglutide sodium and acetate are different forms from the active ingredient in approved products; FDA says they should not be used for semaglutide compounding. FDA: active ingredients and dosing. Products sold as “research peptides” are not a safe substitute for prescribed, regulated treatment. FDA: concerns about unapproved GLP-1 products.

Retatrutide and the next generation of treatment

Retatrutide activates GIP, GLP-1, and glucagon receptors. In the phase 3 TRIUMPH-1 publication in September 2026, adults without diabetes assigned to 12 mg lost an average of 25.0% at 80 weeks, compared with 3.9% with placebo. This is a study result, not an approved treatment claim; different statistical analyses can yield different headline percentages. Gastrointestinal effects and treatment discontinuation remain relevant. TRIUMPH-1.

As of this review, retatrutide remains investigational. Its regulatory status has also become the subject of a dispute between Lilly and FDA.

Why Lilly and FDA disagree about the word “biologic”

The legal dispute concerns which approval pathway retatrutide would use. A biologic is a regulatory category, not a promise that a medicine is more effective, more natural, or safer. FDA’s definition of a protein includes a specifically defined chain of more than 40 alpha-amino acids. The question is how retatrutide fits that definition—or the separate statutory category of a product analogous to a protein. FDA: biologics framework; district-court opinion.

On September 30, 2025, a federal district court upheld FDA’s conclusion that retatrutide was not a protein under its regulation. The court set aside the agency’s reasoning on whether it was analogous to a protein and sent that question back for reconsideration. This was a partial ruling, not an order declaring retatrutide a biologic. Eli Lilly v. Kennedy, September 30, 2025.

Retatrutide’s main chain has 39 alpha-amino acids. Lilly counts additional side-chain components in support of biologic status; FDA disputes that count. In its October 2, 2026 letter, filed in the appeal on October 8, FDA again found retatrutide neither a protein nor analogous to one. This is a classification decision, not a decision granting or denying permission to market the medicine. FDA’s determination on reconsideration.

The distinction matters for future competition. An eligible original biologic can have a 12-year period before a biosimilar approval relying on it may take effect. A qualifying new chemical entity follows a different framework, including five-year exclusivity. These are regulatory protections, separate from patents; they do not mean that every competing medicine is prohibited for exactly 12 or five years. Nor do they establish a future retail price. FDA: reference-product exclusivity; FDA: patents and drug exclusivity.

Compounding is another consequence. Biological products do not qualify for the drug-compounding exemptions in sections 503A and 503B. FDA has a separate policy for certain mixing, dilution, or repackaging of licensed biologics; that does not authorize manufacturing an unapproved alternative from raw peptide powder. Classification as an ordinary drug would not automatically make every compounded version lawful either. FDA: compounding questions and answers.

For a patient deciding what to buy today, the immediate point is simpler: retatrutide remains investigational, and FDA states that it cannot be used in compounding under federal law. A seller’s “research use only” label, prescription, or claim of a laboratory purity test does not establish an approved treatment. The dispute may affect future access and competition; it does not validate products currently offered online. FDA: unapproved GLP-1 drugs.

Regulatory information checked October 17, 2026. Court and agency developments may change the filing pathway; they do not predict an approval date or an affordable price.

What needs checking before treatment

Semaglutide, tirzepatide, and orforglipron carry boxed warnings about a potential risk of thyroid C-cell tumors; the relevance to humans is uncertain. The animal findings differ: the Foundayo label states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in them; its warning considers findings with other GLP-1 receptor agonists. These medicines are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. This is more specific than “any thyroid problem.” Routine thyroid ultrasound or calcitonin testing is not a proven substitute for an appropriate history. MedlinePlus: semaglutide injection; Foundayo label, section 5.1.

Review severe gastroparesis, pancreatitis, gallbladder disease, dehydration risk, allergies, and other medicines. Insulin or sulfonylureas may need adjustment to reduce hypoglycemia risk. People with diabetic retinopathy may need closer eye follow-up. Tell the anesthesia team before a procedure: delayed stomach emptying can affect aspiration risk, and the plan must be individualized. MedlinePlus: tirzepatide.

Pregnancy and contraception

Weight-loss medicines are not used to pursue weight loss during pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy. Discuss pregnancy planning and breastfeeding before starting any treatment. MedlinePlus: semaglutide.

Tirzepatide users taking oral hormonal contraception should add a barrier method or switch to nonoral contraception for four weeks after starting and four weeks after every dose increase. Foundayo has a similar precaution for 30 days after starting and each escalation. Zepbound label; Foundayo label.

Protecting strength and adequate nutrition

Weight loss includes some lean tissue as well as fat. Reduced appetite can make it difficult to obtain enough protein, fluids, and other nutrients. The aim is to reduce excess fat while preserving function, not to eat as little as possible.

Include protein-containing foods across meals and build strength training into the plan as your health allows. Protein targets need adjustment for body size, age, diet, and kidney function; there is no single number suitable for everyone. Persistent weakness, very low food intake, or rapidly declining function should prompt review. Older adults and people with frailty need particular care. Protein supplements alone do not replace resistance exercise. Joint U.S. societies’ advisory on nutrition during GLP-1 treatment.

Side effects and common misunderstandings

Nausea, constipation, diarrhea, reflux, and vomiting can occur, particularly during escalation. A slower increase or a lower maintenance dose may be appropriate. Severe nausea is not proof of effectiveness, and persistent vomiting should never be treated as an acceptable price of weight loss.

Gallbladder problems can occur with these medicines and with substantial weight loss. Pancreatitis is a recognized warning, although most abdominal symptoms have other causes. Seek prompt medical assessment for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, or signs of a serious allergic reaction.

There is no universal rule that losing more than two pounds in a week is dangerous; early fluid changes and starting weight affect the rate. What matters is the pattern, symptoms, hydration, nutrition, and strength. Hair shedding may accompany weight loss and inadequate intake, but other causes should be considered rather than automatically blaming drug toxicity.

Mental health should remain part of follow-up. In January 2026, FDA requested removal of the suicidal behavior and ideation warning from affected GLP-1 labels after its review found no increased risk. That finding does not make depression or new psychological symptoms unimportant. FDA safety review.

Benefits beyond weight loss

Some benefits have been measured as clinical events rather than just changes on the scale. In SELECT, adults with established cardiovascular disease and overweight or obesity, without diabetes, had fewer cardiovascular deaths, nonfatal heart attacks, or nonfatal strokes with semaglutide: 6.5% versus 8.0% over an average 39.8 months of follow-up. The hazard ratio was 0.80; the observed absolute difference was 1.5 percentage points. This is evidence for that high-risk population, not a guarantee of prevention in every otherwise healthy person. SELECT.

Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Sleep assessment and appropriate airway treatment remain necessary; do not stop PAP therapy solely because weight is falling. FDA: sleep apnea indication.

Liver and kidney disease

Wegovy injection has accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis in adults. Approval was based on improvements in liver inflammation and scarring on biopsy; confirmation of longer-term clinical benefit is still required. This is not an indication to treat every abnormal liver test with semaglutide. FDA: MASH approval.

Semaglutide has also shown kidney benefits in people with type 2 diabetes and chronic kidney disease. Those results concern a defined high-risk population and should not be presented as a general kidney-protection promise for anyone seeking weight loss. FLOW trial.

Cancer and metastasis research

Research into cancer outcomes is developing. A 2026 observational breast cancer study found associations between GLP-1 use and lower recorded recurrence and mortality. Such analyses can be affected by differences between patients, treatment timing, and diagnostic coding. They do not prove that semaglutide or tirzepatide prevents recurrence or metastasis. These drugs should not be prescribed as cancer treatment or replace oncology care. Tatum and colleagues, JAMA Network Open.

Maintaining the benefit

Obesity usually requires long-term management. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss during the year after semaglutide and the study lifestyle intervention were stopped. That does not mean everyone regains the same amount, but it argues against presenting treatment as a brief course that permanently resets appetite. STEP 1 extension.

The ADA’s 2026 diabetes standards recommend continuing effective chronic obesity pharmacotherapy beyond reaching weight goals, while individualizing dose and tolerability. This guidance specifically addresses people with diabetes or at risk for it. Continued treatment should remain worthwhile: benefit, side effects, nutrition, preferences, and affordability need reassessment. If medication must stop, plan the transition and follow-up rather than treating weight recurrence as a personal failure. ADA Standards of Care 2026.

Preparing for a consultation

Bring your medication list, recent relevant laboratory results, a short weight history, and details of previous treatments, including their benefits and side effects. If you already use an injectable medicine, bring its exact name, concentration, dose, device or vial information, and dispensing pharmacy. Bring your insurance coverage information or a realistic monthly medication budget as well.

A treatment discussion should establish your priorities, whether medication is appropriate, what will be monitored, and how concerns will be handled. Bariatric surgery, eating-disorder treatment, or specialized nutritional support may call for another member of the care team. After surgery, nutritional deficiencies, existing conditions, and weight recurrence still require medical attention; medication may be part of that care.

Training and a personal perspective

I obtained American Board of Obesity Medicine certification in January 2023 and ABLM/IBLM lifestyle medicine certification in December 2022. Obesity medicine certification is additional professional training and assessment; it does not replace medical licensure or guarantee a particular outcome. Patients can check the ABOM directory and the relevant state medical board. Continuing certification requires ongoing learning and fulfillment of the board’s requirements.

I also know weight management personally. My weight reached 110 kg, about 243 pounds, in January 2022. Over the following three years I reduced it to 72 kg, about 159 pounds, and have maintained that result. My experience has included behavioral approaches, meal replacements, and medication; tirzepatide, nutrition, and physical activity now help me maintain it. This is my own history, not an expected result for every patient. It reinforces why I consider both the initial loss and the practical work of maintaining it.

Sources and review date

Reviewed October 17, 2026. Primary studies, U.S. prescribing information, and official guidance are linked beside the relevant statements. Useful starting points are NIDDK’s medication guide, the ADA obesity standards, and the current Wegovy, Zepbound, and Foundayo labels. Pricing programs and coverage rules can change sooner than clinical guidance.